-DigiTimes
Tonix Pharmaceuticals Announces Statistically Significant And Clinically Meaningful Topline Results In Second Phase 3 Clinical Trial Of TNX-102 SL For The Management Of Fibromyalgia
Phase 3 RESILIENT study of TNX-102 SL successfully demonstrated daily pain reduction over placebo (primary endpoint, p = 0.00005) All six key secondary endpoints, including patient global impression,